Home / Market News / $MEDS

$MEDS news and market catalysts

The 7 most recent market catalysts affecting $MEDS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 4 high impact 5 bullish 2 bearish Healthcare
Sep 18, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Friday's After-Market Session
This filing, generated by an automated content engine, simply reports the after-market price changes for a selection of healthcare stocks. It does not provide the underlying reason…
Sep 17, 2026 Corporate Catalyst Bearish Impact 65
Nebius Group, DataMEDS AI, Boeing, Generac Holdings and Delixy Holdings: Why These 5 Stocks Are on Investors' Radars Today
The filing details several distinct corporate catalysts driving investor interest in these five stocks. Nebius Group (NBIS) is benefiting from a strategic partnership with Palantir…
Sep 16, 2026 Corporate Catalyst Bullish Impact 95
DataMEDS AI Stock Surges Wednesday: What's Driving the Action?
DataMEDS AI's acquisition of Helomics Corporation is a significant corporate catalyst. This move immediately thrusts DataMEDS into the lucrative $40 billion U.S. cancer diagnostic …
Sep 16, 2026 Corporate Catalyst Bullish Impact 95
Market-Moving News for September 16th
The filing highlights three distinct corporate catalysts. DataMEDS (MEDS) experienced a massive 181% surge due to its acquisition of Helomics AI Cancer Diagnostics Lab and Precisio…
Sep 16, 2026 Corporate Catalyst Bullish Impact 92
DataMEDS AI Stock Soars 65% Pre-market: Here's What You Need to Know
DataMEDS AI (MEDS) announced the completion of its acquisition of Helomics Corp., an AI-driven cancer diagnostics laboratory, from Axe Compute Inc. (AGPU) for $1.5 million. This is…
Aug 17, 2026 Corporate Catalyst Bearish Impact 95
DataMEDS AI Q2 EPS $(7.13) Down From $(5.40) YoY, Sales $1.780M Down From $7.791M YoY
DataMEDS AI reported a substantial increase in losses per share, from $(5.40) to $(7.13) year-over-year, alongside a dramatic 77.15% drop in sales from $7.791 million to $1.780 mil…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
DataMeds AI, Datavault AI Amend Definitive Agreement To Expand PharmacyChain Blockchain-Related Technology Licensing Relationship Beyond Pharmaceutical Distribution
DataMeds AI and Datavault AI have expanded their existing definitive agreement, allowing DataMeds AI to license Datavault AI's PharmacyChain blockchain technology for a much wider …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.